(24)Commission Implementing Regulation (EU) 2024/324note extended the approval period of the active substance pyraclostrobin until 15 September 2025, and the approval period of the active substance buprofezin until 15 December 2025.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.